NPM1+ /FLT3- Acute Myeloid Leukemia after JAK2-V617F+ Essential Thrombocythemia. Management and Prognosis

NPM1+ /FLT3- Acute Myeloid Leukemia after JAK2-V617F+ Essential Thrombocythemia. Management and Prognosis

NPM1+ AML after Essential Thrombocythemia (ET) or Myeloproliferative neoplasms is extremely rare. Only 2 cases have been previously reported after Primary Myelofibrosis. Given the extremely poor prognosis of the Blastic phase of Myeloproliferative neoplasms (MPN-BP), the only curative treatment of t...

Full description

Bibliographic Details
Main Authors: Baldomero Moriano, Eva Barragan, Oscar Ferré, Ignacio Casas, Julio Prieto-Fernandez, Carmen Hernandez, Sara Cáceres, Sara Suárez, Rocío Cardesa, María José Arcos, Helena Bañas, Juan Miguel Bergua
Format: Article
Language:English
Published: SAGE Publishing 2021-06-01
Series:Plasmatology
Online Access:https://doi.org/10.1177/26348535211028192

Internet

https://doi.org/10.1177/26348535211028192

Similar Items